Allergan is restructuring and will eliminate 1,000 jobs as part of an effort to reduce costs. The job cuts will affect employees in commercial and other functions. The company is also eliminating 400 open positions. As a result, Allergan expects to save $300 to $400 million in 2018. Severance expenses are expected to cost $125 million, most of which is expected to be recorded in the fourth quarter.
 
In November, the company announced plans to implement a restructuring program in an effort to become even more efficient.

Allergan, based in Dublin, Ireland, had $14.6 billion in revenues in 2016. Its top selling products are Restasis for dry eye and Botox, a cosmetic filler with pharmaceutical indications for chronic migraine, overactive bladder.

In 2016, Allergan sold its generics business to Teva for approximatley $40 billion. Allergan was active on the acquisition front in 2016, picking up a handful of biotechs to bolster its pipeline.